PharmaCyte Biotech announces 1-for-19 reverse stock split
PMCB•PharmaCyte Biotech will complete a 1-for-19 reverse stock split effective November 12, 2026, with adjusted trading starting November 13. The split will reduce outstanding shares from approximately 10.8 million to 566,087 as the company seeks to meet Nasdaq’s minimum bid price requirement.
1. Split details
PharmaCyte Biotech will implement a 1-for-19 reverse stock split effective at 4:01 p.m. Eastern Time on November 12, 2026. Split-adjusted trading will begin November 13 on the Nasdaq Capital Market under the existing ticker PMCB. Outstanding common shares will fall from approximately 10,755,649 to 566,087, while authorized shares will remain unchanged. Holders who would otherwise receive fractional shares will instead receive cash based on the split-adjusted November 12 closing price.
